...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >CCK(2) receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic.
【24h】

CCK(2) receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic.

机译:CCK(2)受体拮抗剂包含构象受限的苯丙氨酸衍生物,包括新氨基酸Xic。

获取原文
获取原文并翻译 | 示例
           

摘要

The conformationally constrained analogues of phenylalanine, tetrahydroisoquinoline-3-carboxylic acid (Tic), Sic, Hic and Nic, and the new amino acid Xic have been incorporated into a potent and highly selective cholecystokinin-2 (CCK(2)) receptor antagonist (2) in place of the phenylalanine residue, producing compounds 15a-e. High selectivities for CCK(2) over CCK(1) were observed for compounds 15a-e. The in vitro profile of the analogue containing the Nic residue (15d) was identical to that of compound 2, whereas the alternative conformational constraints resulted in a significant loss of affinity. The apparent advantage of Nic in the context of these CCK(2) ligands was subsequently demonstrated to be statistically significant.
机译:苯丙氨酸,四氢异喹啉-3-羧酸(Tic),Sic,Hic和Nic以及新氨基酸Xic的构象受约束类似物已被掺入有效且高度选择性的胆囊收缩素2(CCK(2))受体拮抗剂中( 2)代替苯丙氨酸残基,产生化合物15a-e。对于化合物15a-e,与CCK(1)相比,CCK(2)的选择性高。含有Nic残基的类似物(15d)的体外概况与化合物2相同,而其他构象约束条件则导致亲和力显着降低。 Nic在这些CCK(2)配体的上下文中的明显优势随后被证明具有统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号